The ACE inhibitor S9650 effectively produces dose-dependent inhibition of vascular ACE in both brain and mesenteric microvessels in a rat model.
Answers are grounded in this paper and cite their sources.
Supports S9650 preclinical testing for microvessel ACE inhibition; leaves open human translation and clinical relevance.
Angiotensin-converting enzyme (ACE) was measured in the aorta, cerebral and mesenteric microvessels of Wistar-Kyoto rats using a specific radioligand assay. 2. Ligand binding studies revealed a four-fold increase in concentration of ACE in mesenteric microvessels, compared with aorta or brain microvessels. The dissociation constant (Kd) was similar in all tissues. 3. The effects of oral administration of the ACE inhibitor S9650 on vascular ACE in vivo were measured. 4. S9650 produced a dose-dependent inhibition of vascular ACE from brain and mesenteric microvessels.
No takes yet. Share an insight, caveat, or question.
Jandeleit et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: